Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital

被引:0
|
作者
Tariverdi, Marjan [1 ]
Mohammadi, Hossein [2 ]
Hassanzadeh, Farideh [3 ]
Tamaddondar, Mohammad [4 ]
机构
[1] Hormozgan Univ Med Sci, Fac Med, Dept Pediat, Bandar Abbas, Iran
[2] Hormozgan Univ Med Sci, Student Res Comm, Bandar Abbas, Iran
[3] Hormozgan Univ Med Sci, Childrens Hosp, Clin Res Dev Ctr, Dept Pediat, Bandar Abbas, Iran
[4] Hormozgan Univ Med Sci, Shahid Mohammadi Hosp, Dept Nephrol & Internal Med, Bandar Abbas, Iran
关键词
COVID-19; Healthcare workers; Seroprevalence; Vaccination; SARS-COV; COVID-19; EFFICACY;
D O I
10.1186/s12879-023-08863-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundHealthcare workers (HCWs) have a higher risk of contracting coronavirus disease 2019 (COVID-19) compared to the general population due to their frontline role and direct contact with the infected patients. Accordingly, they were among the first groups to receive vaccination against COVID-19. A higher risk of COVID-19 infection may also exist among hospital staff members other than HCWs. In this study, we assessed the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG pre- and post-COVID-19 vaccination in hospital staff members.MethodsThis cross-sectional study included 228 staff members of Bandar Abbas Children's Hospital, Bandar Abbas, Iran, who were recruited from 2020 to 2021. Staff members were vaccinated with vector and inactivated vaccines. Anti-SARS-CoV-2 spike protein IgG was measured in their blood samples pre- and post-COVID-19 vaccination.ResultsOf the 228 hospital staff members evaluated in this study (mean age: 37.59 +/- 8.70 years), 204 (89.5%) were female and 210 (92.1%) were HCWs. Only one staff member was not vaccinated, the rest received one dose (99.6%), and 224 (98.7%) two doses. Vector vaccines were administered to 71.4% of staff members and 72.9% of HCWs. Anti-SARS-CoV-2 IgG antibody was positive in 8.8% of staff members before vaccination, 9.3% after the first dose, and 50% after the second dose. The corresponding percentages were 9.5%, 9.5%, and 48.8% in HCWs. Being a HCW was not associated with the seroprevalence of anti-SARS-CoV-2 IgG after the second dose; however, multivariable binary logistic regression analysis revealed that the interval between two vaccine doses (adjusted odds ratio [aOR] = 0.595, 95% confidence interval [CI] 0.434; 0.816, P = 0.001) and age (aOR = 1.062, 95% CI 1.021; 1.105, P = 0.003) were associated with seroprevalence.ConclusionsAfter receiving a second dose of vector or inactive virus vaccines, our hospital's staff members and HCWs had a seroprevalence of anti-SARS-CoV-2 IgG antibodies of around 50%. Seroprevalence increased with increasing age and shorter intervals between doses.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination
    Tretyn, Andrzej
    Szczepanek, Joanna
    Skorupa, Monika
    Jarkiewicz-Tretyn, Joanna
    Sandomierz, Dorota
    Dejewska, Joanna
    Ciechanowska, Karolina
    Jarkiewicz-Tretyn, Aleksander
    Koper, Wojciech
    Palgan, Krzysztof
    CELLS, 2021, 10 (08)
  • [2] KINETICS OF ANTI-SARS-COV-2 IGG ANTIBODIES POST-COVID-19-VACCINATION
    Kamal, S.
    Naguib, M.
    Daador, M.
    Alanazi, Z.
    Basalem, A. Abdullah
    Alaskar, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S84 - S84
  • [3] Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines
    Ebrahim, Fawzi
    Tabal, Salah
    Lamami, Yosra
    Alhudiri, Inas M.
    El Meshri, Salah Edin
    Al Dwigen, Samira
    Arfa, Ramadan
    Alboeshi, Asma
    Alemam, Hafsa A.
    Abuhtna, Fauzia
    Altrhouni, Rabeeah
    Milad, Mohamed B.
    Elgriw, Nada A.
    Ruaua, Mahmoud A.
    Abusrewil, Zakarya
    Harroush, Warda
    Jallul, Mwada
    Ali, Fouziyah S.
    Eltaib, Farag
    Elzagheid, Adam
    VACCINES, 2022, 10 (12)
  • [4] Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
    Carlos David Araújo Bichara
    Ednelza da Silva Graça Amoras
    Gergiane Lopes Vaz
    Maria Karoliny da Silva Torres
    Maria Alice Freitas Queiroz
    Isabella Pinheiro Costa do Amaral
    Izaura Maria Vieira Cayres Vallinoto
    Cléa Nazaré Carneiro Bichara
    Antonio Carlos Rosário Vallinoto
    BMC Infectious Diseases, 21
  • [5] Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
    Araujo Bichara, Carlos David
    Graca Amoras, Ednelza da Silva
    Vaz, Gergiane Lopes
    da Silva Torres, Maria Karoliny
    Freitas Queiroz, Maria Alice
    Costa do Amaral, Isabella Pinheiro
    Vieira Cayres Vallinoto, Izaura Maria
    Carneiro Bichara, Clea Nazare
    Rosario Vallinoto, Antonio Carlos
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [6] Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings
    Buonsenso, Danilo
    Valentini, Piero
    De Rose, Cristina
    Pata, Davide
    Sinatti, Dario
    Speziale, Domenico
    Ricci, Rosalba
    Carfi, Angelo
    Landi, Francesco
    Ferrari, Vittoria
    De Maio, Flavio
    Palucci, Ivana
    Sanguinetti, Maurizio
    Sali, Michela
    PEDIATRIC PULMONOLOGY, 2021, 56 (06) : 1374 - 1377
  • [7] Anti-SARS-CoV-2 IgG antibodies pre- and post-vaccination behavior in health workers from a Guatemalan cancer center
    Carias-Alvarado, Cesar C.
    Lopez-Hun, Francisco
    Valvert, Fabiola
    Barrios-Menendez, Juan C.
    Kihn-Alarcon, Alba
    de Falla, Vicky
    Xu, Ximing
    Escobar-Castro, Karla
    GACETA MEDICA DE MEXICO, 2022, 158 (02): : 81 - 85
  • [8] Answer to the letter to the editor "About anti-SARS-CoV-2 IgG antibodies pre- and post-vaccination behavior in health workers"
    Carias-Alvarado, Cesar C.
    Lopez-Hun, Francisco
    Valvert, Fabiola
    Barrios-Menendez, Juan C.
    Kihn-Alarcon, Alba
    De Falla, Vicky
    Xu, Ximing
    Escobar-Castro, Karla
    GACETA MEDICA DE MEXICO, 2022, 158 (05): : 347 - 347
  • [9] Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients
    Hiki, Makoto
    Tabe, Yoko
    Ai, Tomohiko
    Matsue, Yuya
    Harada, Norihiro
    Sugimoto, Kiichi
    Matsushita, Yasushi
    Matsushita, Masakazu
    Wakita, Mitsuru
    Misawa, Shigeki
    Idei, Mayumi
    Miida, Takashi
    Tamura, Naoto
    Takahashi, Kazuhisa
    Naito, Toshio
    PLOS ONE, 2021, 16 (04):
  • [10] Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors
    Uyoga, Sophie
    Adetifa, Ifedayo M. O.
    Karanja, Henry K.
    Nyagwange, James
    Tuju, James
    Wanjiku, Perpetual
    Aman, Rashid
    Mwangangi, Mercy
    Amoth, Patrick
    Kasera, Kadondi
    Ng'ang'a, Wangari
    Rombo, Charles
    Yegon, Christine
    Kithi, Khamisi
    Odhiambo, Elizabeth
    Rotich, Thomas
    Orgut, Irene
    Kihara, Sammy
    Otiende, Mark
    Bottomley, Christian
    Mupe, Zonia N.
    Kagucia, Eunice W.
    Gallagher, Katherine E.
    Etyang, Anthony
    Voller, Shirine
    Gitonga, John N.
    Mugo, Daisy
    Agoti, Charles N.
    Otieno, Edward
    Ndwiga, Leonard
    Lambe, Teresa
    Wright, Daniel
    Barasa, Edwine
    Tsofa, Benjamin
    Bejon, Philip
    Ochola-Oyier, Lynette, I
    Agweyu, Ambrose
    Scott, J. Anthony G.
    Warimwe, George M.
    SCIENCE, 2021, 371 (6524) : 79 - 82